Research graph
References from Preclinical and clinical outcomes in patients with high rheumatoid factor levels treated with TNF inhibitors:a systematic review. Local targets link to admitted publications; unresolved targets remain external evidence.
Unresolved reference
External reference
Exploring the influence of baseline rheumatoid factor levels on TNF inhibitor retention rate in patients with rheumatoid arthritis: a multicentre and retrospective study
10.1136/rmdopen-2023-003975 · 2024 · External reference
Rheumatoid factor and rheumatoid arthritis
10.1016/j.jcot.2019.03.007 · 2019 · External reference
In early rheumatoid arthritis, anticitrullinated peptide antibodies associate with low number of affected joints and rheumatoid factor associates with systemic inflammation
10.1136/ard-2023-224728 · 2024 · External reference
Influence of rheumatoid factor on serum drug levels of TNF inhibitors with different structures in rheumatoid arthritis
2024 · External reference
A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis
10.1093/rheumatology/kep155 · 2009 · External reference
Rheumatoid factor determines structural progression of rheumatoid arthritis dependent and independent of disease activity
10.1136/annrheumdis-2012-201517 · 2013 · External reference
Rheumatoid factor isotypes in rheumatoid arthritis diagnosis and prognosis: a systematic review and meta-analysis
10.1136/rmdopen-2022-002817 · 2023 · External reference
The Status of Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Antibody Are Not Associated with the Effect of Anti-TNFα Agent Treatment in Patients with Rheumatoid Arthritis: A Meta-Analysis
10.1371/journal.pone.0089442 · 2014 · External reference
Ozoralizumab: First Approval
10.1007/s40265-022-01821-0 · 2023 · External reference
Impact of high rheumatoid factor levels on treatment outcomes with certolizumab pegol and adalimumab in patients with rheumatoid arthritis
10.1093/rheumatology/keae435 · 2024 · External reference
10.1186/s13075-017-1401-2
10.1186/s13075-017-1401-2 · 2017 · External reference
Unresolved reference
2009 · External reference
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
2021 · External reference
Unresolved reference
2008 · External reference
2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative
10.1136/ard.2010.138461 · 2010 · External reference
Impact of dual rheumatoid factor and anti-citrullinated protein antibody seropositive, single seropositive, and seronegative rheumatoid arthritis on outcomes
10.1002/acr.80009 · 2026 · External reference
Differential efficacy of TNF inhibitors with or without the immunoglobulin fragment crystallizable (Fc) portion in rheumatoid arthritis: the ANSWER cohort study
10.1007/s00296-021-05086-w · 2022 · External reference
Unresolved reference
External reference
Assessing risk of bias in a randomized trial
10.1002/9781119536604.ch8 · 2019 · External reference
Unresolved reference
External reference
POS0722 Purified monoclonal rheumatoid factors bind Fc containing TNF inhibitors in vitro but not the Fc-free TNF inhibitor, Certolizumab Pegol
10.1136/annrheumdis-2024-eular.2568 · 2024 · External reference
Unresolved reference
External reference
Immunoglobulin G structure and rheumatoid factor epitopes
10.1371/journal.pone.0217624 · 2019 · External reference
A novel TNF inhibitor ozoralizumab is unaffected by rheumatoid factor in the recycling mechanism via neonatal Fc receptor
2025 · External reference
Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFα therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement
10.1136/ard.2003.014647 · 2004 · External reference
Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment
10.1007/s00296-004-0571-9 · 2005 · External reference
Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis
10.1136/ard.2004.023523 · 2005 · External reference
W43-5: usefulness of certolizumab pegol useful rheumatoid arthritis with high rheumatoid factor
2024 · External reference
ABS1004 Unraveling the influence of rheumatoid factor on RA treatment success
10.1016/j.ard.2025.06.1633 · 2025 · External reference
Influence of rheumatoid factors on the efficacy of TNF inhibitor therapy in patients with rheumatoid arthritis
10.1007/s40744-025-00769-3 · 2025 · External reference
Treatment response in patients with rheumatoid arthritis treated certolizumab pegol based on rheumatoid factor levels
2025 · External reference
Do high rheumatoid factor levels impact response to certolizumab pegol in patients with inadequately controlled rheumatoid arthritis? A post hoc analysis of the phase 3b realistic trial
10.1136/annrheumdis-2024-eular.2883 · 2024 · External reference
Ozoralizumab shows effectiveness regardless of baseline RF and ACPA titres in patients with RA: a post hoc analysis of the OHZORA trial
10.1093/rheumatology/keaf171 · 2025 · External reference
Certolizumab inhibits radiographic progression even in RA patients with high rheumatoid factor levels: a pooled, post-hoc analysis of two phase 3 trials
2024 · External reference
Efficacy of certolizumab pegol across baseline rheumatoid factor subgroups in patients with rheumatoid arthritis: post-hoc analysis of clinical trials
10.1111/1756-185x.14699 · 2023 · External reference
Influence of rheumatoid factor levels and TNF inhibitor structure on secondary nonresponse in rheumatoid arthritis patients
10.3389/fmed.2024.1461396 · 2024 · External reference
Fragment crystallizable (Fc)-free certolizumab pegol is not bound by rheumatoid factors, while fc containing biological DMARDsAre, driving immunecomplex formation and cellular clearance
2024 · External reference
Interaction of the rheumatoid factor with antigen-antibody complexes and aggregated gamma globulin
10.1084/jem.108.1.105 · 1958 · External reference
Immunogenicity of biologics in chronic inflammatory diseases: a systematic review
10.1007/s40259-017-0231-8 · 2017 · External reference
Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry
10.1136/ard-2023-225271 · 2024 · External reference
Use of clinical disease activity index score for assessment of disease activity in rheumatoid arthritis patients: an Indian experience
2011 · External reference
A simplified disease activity index for rheumatoid arthritis for use in clinical practice
10.1093/rheumatology/keg072 · 2003 · External reference
American College of Rheumatology/EULAR remission criteria for rheumatoid arthritis: 2022 revision
10.1136/ard-2022-223413 · 2023 · External reference
Rheumatoid factors (RFs) in RA patient sera do not bind to Fc-free certolizumab pegol, but do bind to Fc-containing anti-TNF-α biological DMARDs, driving immune complex formation and cellular clearance [abstract]
2025 · External reference
Certolizumab pegol does not bind the neonatal Fc receptor (FcRn): consequences for FcRn-mediated in vitro transcytosis and ex vivo human placental transfer
10.1016/j.jri.2016.04.284 · 2016 · External reference
Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis
2017 · External reference
10.1002/art.21519
10.1002/art.21519 · 2006 · External reference
Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial
10.1016/s0140-6736(04)15640-7 · 2004 · External reference
Comparative efficacy of novel DMARDs as monotherapy and in combination with methotrexate in rheumatoid arthritis patients with inadequate response to conventional DMARDs: a network meta-analysis
2015 · External reference
Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register
10.1136/ard.2010.139774 · 2011 · External reference
